Do You Need to Adjust Your HRT Dose Over Time?

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient asked me something last spring that I wish more women asked out loud. She'd been on hormone therapy for almost three years. Felt good for most of it. Then, somewhere around month thirty, the night sweats started creeping back. Not like before, but enough to wake her twice a week. Her question was this: "Did my dose stop working, or did I stop needing it?"

Those are two completely different problems with two opposite solutions, and telling them apart is a real part of the work. I'm Dr. Farhan Abdullah, and I practice internal medicine and functional medicine at Magnolia Functional Wellness here in Southlake. A good portion of what I do on the hormone side isn't starting therapy at all. It's tuning it, year over year, as the woman in front of me changes.

Because she does change. That's the part nobody explains well at the first visit. The dose that fixes your symptoms at 49 was never meant to be the dose you carry to 62.

Why Your Dose Isn't Supposed to Stay Put

Menopause isn't an event. It's a transition with a long tail, and your body keeps moving through it well after your last period.

In late perimenopause, your ovaries are still sputtering out estrogen in unpredictable bursts. Some months you make a fair amount, some months almost none. Therapy started in that window is layered on top of a shifting baseline. Two or three years into postmenopause, that residual ovarian output is essentially gone, and the same external dose now lands on a much quieter background. Sometimes that means you need less, because there's no longer a chaotic surge stacking on top. More often it means the reverse.

Absorption shifts too, and this one surprises people. Transdermal estradiol crosses through skin, and skin changes with age, body composition, and even the season. I've had patients in Southlake tell me their patch adheres beautifully in January and slides off by mid-July, which sounds like a punchline until you're the one losing four hours of coverage a day to Texas humidity. Weight change alters distribution. So does starting or stopping a thyroid medication, or a statin, or anything that moves hepatic metabolism.

Then there's the question of what you're treating. The goal at year one is usually symptom rescue: stop the hot flashes, give me back my sleep, make my brain work again. By year four the target has often quietly shifted toward bone protection, genitourinary symptoms, and maintenance. Different goals can justify different doses.

What I tell my patients is that the starting dose is a hypothesis. A well-reasoned one, based on your symptoms and history, but still a hypothesis. The follow-up visits are where we find out whether we were right.

The Signs Your Dose Deserves a Second Look

Women are generally very good at noticing that something shifted. They're less sure whether it's worth mentioning. It usually is.

Signals that you may be running low:

• Vasomotor symptoms returning after a stretch of good control, especially at night
• Sleep that fragments in the early morning hours even though falling asleep is fine
• Joint stiffness and aching that came back without a new injury
• Mood volatility or a flat, unmotivated feeling that tracks with the calendar rather than with your life
• Vaginal dryness, urinary urgency, or discomfort with intimacy that had previously resolved
• Brain fog returning, particularly word-finding trouble

Signals that you may be running high:

• Breast tenderness or fullness, particularly if it's new after months of stability
• Bloating, fluid retention, or rings that stopped fitting
• Headaches, especially ones that cluster around a dose change or a pellet insertion
• Nausea, most common with oral routes
• Irritability or a wired, edgy quality to your energy
• Acne or unwanted hair growth, which usually points at the testosterone component rather than the estrogen

Timing matters as much as the symptom itself. A woman on a twice-weekly patch who reliably feels worse on day three has a coverage problem, not necessarily a dose problem. A woman on pellets who feels wonderful for eight weeks and rough for the last four has an interval problem. Those get solved differently, and if you only track "how do I feel," you miss the pattern. I ask patients to note the day, not just the symptom.

One exception that isn't negotiable: any new vaginal bleeding after menopause gets evaluated, not dose-adjusted. Not reassured over the phone, not assumed to be the progesterone, not watched for a few months. Evaluated. Most of the time it's benign. The reason we look every time is the small percentage of the time it isn't.

What the Evidence Actually Supports

The honest summary is that guidelines endorse individualization and periodic reassessment, and they've moved away from the rigid rules many women were given a decade ago.

The clearest statement of this comes from the 2022 hormone therapy position statement of The North American Menopause Society, published in Menopause. It backs an individualized approach, using the appropriate dose, route, and duration for a particular woman's symptoms and risk profile, with regular reevaluation rather than a fixed stopping point. It specifically pushes back on arbitrary duration limits and on the idea that every woman must taper off at a set age. That's a meaningful shift from the advice that circulated in the 2000s.

A lot of that older caution traced back to early readings of the Women's Health Initiative. The long-term follow-up complicated the picture considerably. In a 2017 analysis published in JAMA, Manson and colleagues reported all-cause and cause-specific mortality across roughly 18 years of cumulative follow-up in the WHI randomized trials, and did not find an increase in all-cause mortality among women who had received hormone therapy during the intervention period. That finding doesn't make hormone therapy risk-free, and it doesn't make it right for everyone. What it does is undercut the blanket fear that drove a generation of women off treatment they were tolerating well.

Route is worth understanding separately from dose, because it changes the risk math. In a 2018 meta-analysis in Climacteric, Scarabin examined oral versus transdermal estrogen and venous thromboembolism risk in menopausal women, with attention to the progestogen used alongside it. The broad signal that transdermal delivery avoids first-pass hepatic effects, and carries a different clotting risk profile than oral, is part of why route is one of the first things I look at when a woman has risk factors or when a dose increase makes me hesitate. For a wider clinical overview of how these decisions are framed, Pan and colleagues published a 2022 update on hormone therapy for postmenopausal women in Bioscience Trends.

None of this tells you what your dose should be. That's the limitation of guidelines, and it's why the follow-up visit exists.

How We Actually Adjust a Dose

Symptoms lead. Labs support. I want to be direct about that order, because it gets reversed constantly.

Serum estradiol levels are useful, but they're softer data than most patients assume. Levels fluctuate by time of day, by where you are in a patch cycle or a pellet interval, and by assay. A single number pulled at a random hour tells me less than a careful history does. I check levels to catch outliers and to make sure we're not somewhere absurd in either direction, not to chase a target range printed on a lab report. A woman who feels well at a level of 45 does not need her dose pushed to hit 80.

What I do look at alongside symptoms: estradiol, FSH when the clinical picture is unclear, a lipid panel, thyroid studies, CBC, metabolic panel, and, when testosterone is part of her regimen, a total and free testosterone with SHBG. If she has a uterus, I'm scrutinizing whether the progesterone dose and schedule are genuinely adequate for endometrial protection, because that isn't optional and it doesn't scale automatically when estrogen goes up. Our guide on what "normal" labs actually mean for women's hormones goes deeper on where those reference ranges come from and why they mislead.

Then a few working rules:

Change one variable at a time. If I raise the estradiol and switch the progesterone on the same visit, and she feels different in six weeks, I've learned nothing about which move did it. Tempting, and I resist it.

Give it six to twelve weeks. Tissue response lags serum levels. Vasomotor symptoms often answer within a few weeks, but sleep architecture, mood, and genitourinary tissue take considerably longer. Judging a dose change at three weeks produces a lot of unnecessary second changes.

Consider route before reaching for more. When someone is breaking through on a patch, moving to a different delivery method or adjusting the schedule sometimes solves it at the same total dose. More isn't the only lever.

Go up in small steps. Large jumps overshoot, and overshooting produces breast tenderness and bloating that convinces women hormone therapy doesn't agree with them, when the problem was the size of the increment.

If you want the detail on how we structure the initial workup and follow-up cadence, that's laid out on our women's hormone replacement therapy page.

When Going Down Is the Right Answer

Dose adjustment gets discussed as though it only moves one direction. It doesn't, and some of the most useful conversations I have are about coming down.

Reasonable prompts to reduce: you've had a long, genuinely symptom-free stretch and we've never tested whether you still need the current amount. You've developed a new cardiovascular or clotting risk factor. You've gained or lost substantial weight. A new diagnosis or medication changed the calculus. Or you're simply curious whether your own physiology has settled, which is a legitimate reason to try.

When we lower, we taper rather than stop. Abrupt discontinuation tends to produce a rebound surge of vasomotor symptoms that can be worse than anything she had originally, and that rebound then gets misread as proof she can never come off. A gradual step down over several months distinguishes real ongoing need from withdrawal.

And the question I get constantly: do I have to stop at 65? No. There's no automatic expiration date, and current guidance supports continuing based on an ongoing assessment of benefits and risks rather than on a birthday. What changes after 60 or 65 is that the risk-benefit conversation gets more individualized and route selection matters more. It becomes a yearly discussion, not a discharge notice.

The women who do best on hormone therapy over the long run, in my experience, are the ones who treat it as an ongoing clinical relationship instead of a prescription they refill. They notice patterns. They mention the small stuff. They show up for the follow-up even when they feel fine, because feeling fine is exactly the information I need to decide whether to leave a dose alone or gently test whether it's still necessary. If your hormone therapy hasn't been reassessed in over a year, that's worth a conversation, whether you're with us here in Southlake or with a physician elsewhere who knows your history.